头孢地尔与莫西沙星对铜绿假单胞菌具有相加和协同活性,包括2023年角膜炎暴发的一株分离株
本研究评价头孢地尔与莫西沙星对铜绿假单胞菌角膜炎分离株的体外疗效与协同作用,并评估群体感应缺陷的影响。时间杀菌试验显示两药对7/7株测试分离株呈协同作用;E-test法显示对79%分离株呈相加或协同活性,在疑似群体感应缺陷株中降至60%。头孢他啶与莫西沙星组合效果较差。
要点
- 头孢地尔与莫西沙星在时间杀菌试验中对7/7株铜绿假单胞菌角膜炎分离株呈协同作用。
- E-test法显示两药对79%分离株呈相加或协同活性,疑似群体感应缺陷株中为60%。
- 头孢他啶与莫西沙星组合效果较差,尤其在sheen阳性株中。
核心结论
- 头孢地尔与莫西沙星在体外对大多数测试的铜绿假单胞菌角膜炎分离株表现协同作用,包括疑似群体感应缺陷株。
- 这些发现支持进一步研究该组合用于治疗高度耐药眼部感染。
研究设计与样本
- 体外研究,采用时间杀菌试验和epsilometer(E-test)法测定最低抑菌浓度和药物相互作用。
- 计算分数抑菌浓度指数以将药物相互作用表征为拮抗、无关、相加或协同。
- 通过特征性菌落光泽表型鉴定群体感应缺陷株,该表型与LasR系统缺陷相关。
主要发现
- 时间杀菌研究显示头孢地尔与莫西沙星对7/7株测试的铜绿假单胞菌角膜炎分离株呈一致的协同相互作用,包括一株来自2023年暴发的分离株。
- 基于E-test的试验显示对79%的分离株呈相加或协同活性,但在疑似群体感应缺陷株中降至60%。
- 头孢他啶与莫西沙星组合效果较差,尤其在sheen阳性株中。
- 头孢地尔-莫西沙星组合对粘质沙雷菌和金黄色葡萄球菌呈无关效应,每种抗生素保留各自活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 2023 outbreak of Pseudomonas aeruginosa keratitis linked to contaminated artificial tears highlighted the need for new treatments targeting ocular infections caused by multi-drug-resistant and extensively drug-resistant bacteria. This study evaluated the in vitro efficacy and potential synergy of cefiderocol and moxifloxacin against P. aeruginosa keratitis isolates. The influence of quorum-sensing defects on antibiotic efficacy was also assessed because of the increase in lasR mutant keratitis isolates. Ceftazidime, which lacks the "Trojan Horse" iron-binding-mediated bacterial entry mechanism of cefiderocol, served as a comparator. METHODS: Time-kill and epsilometer (E-test) assays were used to determine minimum inhibitory concentrations and drug interactions. Fractional inhibitory concentration indices were calculated to characterize drug interactions as antagonistic, indifferent, additive, or synergistic. Quorum-sensing defective strains were identified by a characteristic colony sheen phenotype associated with LasR system defects. RESULTS: Time-kill studies demonstrated consistent synergistic interactions between cefiderocol and moxifloxacin against seven out of seven tested P. aeruginosa keratitis isolates, including one from the 2023 outbreak. E-test-based assays showed additive or synergistic activity against 79% of isolates, although this dropped to 60% among suspected quorum-sensing defective strains. In contrast, the ceftazidime and moxifloxacin combination was less effective, particularly sheen-positive strains. The cefiderocol-moxifloxacin combination showed indifferent effects against Serratia marcescens and Staphylococcus aureus, with each antibiotic retaining individual activity. CONCLUSIONS: Cefiderocol and moxifloxacin exhibited synergy against most tested P. aeruginosa keratitis isolates in vitro, including those with suspected quorum-sensing defects. These findings support further investigation of this combination for treating highly drug-resistant ocular infections.
引用
- Romanowski EG, Schilling BM, Young EK, et al. Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak. Invest Ophthalmol Vis Sci. 2025. PMID: 41222202. doi:10.1167/iovs.66.14.19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。